Table 1 Participant baseline characteristics
From: Perioperative redox changes in patients undergoing hepato-pancreatico-biliary cancer surgery
Characteristics | N (%) |
|---|---|
Age (years)a | 67 (60.0–71.7) |
Gender (male, female) | 39, 17 (69.6, 30.4) |
BMI (kg/m2)a | 25.8 (22.9–28.4) |
Ethnicity | |
White | 53 (94.6) |
Asian | 2 (3.6) |
Black | 1 (1.8) |
Smoking status | |
Yes | 5 (8.9) |
No | 31 (55.4) |
Ex-smoker | 20 (35.7) |
Alcohol | |
Yes | 22 (39.3) |
No | 34 (60.7) |
Consumption (units per week)a | 2 (2–10) |
ASA score | |
I | 5 (8.9) |
II | 33 (58.9) |
III | 18 (32.1) |
IV | 0 (0.0) |
Comorbidities | |
Cardiovascular | 33 (59.8) |
Hypertension | 22 (39.3) |
Ischaemic heart disease | 7 (12.5) |
Heart failure | 0 (0.0) |
Arrhythmia | 4 (7.1) |
Valvular heart disease | 0 (0.0) |
Cerebral vascular disease | 2 (3.6) |
Peripheral vascular disease | 2 (3.6) |
Respiratory | 12 (21.4) |
COPD | 7 (12.5) |
Asthma | 3 (5.4) |
OSA | 1 (1.8) |
Other | 1 (1.8) |
Endocrine and metabolic | 27 (48.2) |
Diabetes | 14 (25.0) |
Hypercholesterolaemia | 8 (14.2) |
Other | 5 (8.9) |
Renal disease | 1 (1.8) |
Rheumatological | 4 (7.1) |
Other systemic disease | 3 (5.4) |
Diagnosis | |
Pancreatic cancer | 19 (33.9) |
Liver metastasis | 18 (32.1) |
Cholangiocarcinoma | 7 (12.5) |
Hepatocellular carcinoma | 6 (10.7) |
Neuroendocrine tumour | 2 (3.6) |
Ampulla and duodenal cancer | 2 (3.6) |
Other | 2 (3.6) |
Neoadjuvant chemoradiotherapy within the last year | 15 (26.8) |